F10 and atrial fibrillation: The Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial (ROCKET AF) showed rivaroxaban to have more clinically relevant epistaxis events compared with warfarin, with similar findings in the Japanese ROCKET AF (J-ROCKET AF) trial, although the results were not assessed for statistical significance [1,2].